CD 10367Alternative Names: CD10367
Latest Information Update: 30 Jan 2017
At a glance
- Originator Galderma
- Class Antipsoriatics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Plaque psoriasis
Most Recent Events
- 01 Nov 2015 Phase-II clinical trials in Plaque psoriasis in France (Topical) (NCT03025282)